PCM
CTKB icon

Prelude Capital Management’s Cytek Biosciences CTKB Stock Holding History

Prelude Capital Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$200K Buy
45,259
+32,059
+243% +$137K 0.01% 990
2026
Q1 		$57.7K Sell
13,200
-200
-1% -$944 ﹤0.01% 1118
2025
Q4 		$67.7K Buy
+13,400
New +$62.2K 0.01% 1219
2025
Q2 		– Sell
-19,200
Closed -$77K – 1063
2025
Q1 		$77K Sell
19,200
-9,680
-34% -$50.2K 0.01% 1062
2024
Q4 		$187K Sell
28,880
-7,004
-20% -$41.7K 0.01% 1013
2024
Q3 		$199K Buy
35,884
+18,970
+112% +$108K 0.01% 1074
2024
Q2 		$94.4K Buy
16,914
+1,114
+7% +$6.69K 0.01% 1104
2024
Q1 		$106K Buy
+15,800
New +$125K 0.01% 1195
2023
Q2 		– Sell
-18,172
Closed -$167K – 1169
2023
Q1 		$167K Buy
+18,172
New +$195K 0.01% 891

Other funds holding CTKB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Prelude Capital Management's CTKB Position: Q2 2026 in Review

Prelude Capital Management increased its Cytek Biosciences (CTKB) stake by 243% in Q2 2026, buying an estimated $137K and bringing the position to 45,259 shares worth $200K. The position accounts for 0.01% of the portfolio, ranked #990.

Prelude Capital Management first reported a position in CTKB in Q1 2023 and has held it in 9 quarters since. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

  • Prelude Capital Management held 45,259 shares of Cytek Biosciences worth $200K as of Q2 2026.
  • Prelude Capital Management bought 32,059 Cytek Biosciences shares in Q2 2026, an estimated $137K.
  • Cytek Biosciences made up 0.01% of Prelude Capital Management's portfolio in Q2 2026, its #990 holding.
  • Prelude Capital Management first reported a position in Cytek Biosciences in Q1 2023 and has held it in 9 quarters since.
  • 154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.